^Cohen ML, Bloomquist W, Gidda JS, Lacefield W. LY277359 maleate: a potent and selective 5-HT3 receptor antagonist without gastroprokinetic activity. The Journal of Pharmacology and Experimental Therapeutics. July 1990, 254 (1): 350–5. PMID 2366187.
^Robertson DW, Lacefield WB, Bloomquist W, Pfeifer W, Simon RL, Cohen ML. Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships. Journal of Medicinal Chemistry. January 1992, 35 (2): 310–9. PMID 1732548. doi:10.1021/jm00080a016.
^Smith WT, Londborg PD, Blomgren SL, Tollefson GD, Sayler ME. Pilot study of zatosetron (LY277359) maleate, a 5-hydroxytryptamine-3 antagonist, in the treatment of anxiety. Journal of Clinical Psychopharmacology. April 1999, 19 (2): 125–31. PMID 10211913. doi:10.1097/00004714-199904000-00006.
^Williams PD, Calligaro DO, Colbert WE, Helton DR, Shetler T, Turk JA, Jordan WH. General pharmacology of a new potent 5-hydroxytryptamine antagonist. Arzneimittel-Forschung. March 1991, 41 (3): 189–95. PMID 1867653.
^Bendele A, Means J, Shoufler J, Schmalz C, Hanasono G, Symanowski J, Adams E. Chronic toxicity of zatosetron, a 5-HT3 receptor antagonist, in rhesus monkeys. Drug and Chemical Toxicology. February 1995, 18 (1): 61–82. PMID 7768200. doi:10.3109/01480549509017858.